GlassScriptPhysician profile
Penny Glickman
NPI 1619975638
$12,412.55
in general payments reported to CMS, 2019-2025
52 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,803 · 2020: $3,179 · 2021: $193 · 2022: $349 · 2023: $1,337 · 2024: $1,471 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,829 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.68 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $4,261.92 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $985.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $740.34 | 2019-2025 | |
| Lilly USA, LLC | $676.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $564.19 | 2019-2025 | Evenity, Prolia, Tepezza |
| Ibsa Pharma INC. | $413.42 | 2019-2025 | Tirosint, Licart, Tirosint |
| Abbvie INC. | $365.43 | 2019-2025 | |
| Beta Bionics, INC. | $358.59 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.33 | 2019-2025 | Jardiance, Synjardy |
| Radius Health, INC. | $273.31 | 2020-2025 | Tymlos |
| Cequr Corporation | $263.38 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $261.95 | 2019-2025 | Omnipod |
| Abbott Laboratories | $253.30 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $209.64 | 2019-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $184.27 | 2019-2020 |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Glickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.